Skip to main content

Publisher: Wiley-Blackwell on behalf of the International Society on Thrombosis and Haemostasis

Volume 5, Number 4, April 2007

Free Content A guide to murine platelet structure, function, assays, and genetic alterations
pp. 661-669(9)
Authors: JIROUSKOVA, M.; SHET, A. S.; JOHNSON, G. J.

Favourites:
ADD

Free Content A guide to murine coagulation factor structure, function, assays, and genetic alterations
pp. 670-679(10)
Authors: EMEIS, J. J.; JIROUSKOVA, M.; MUCHITSCH, E.-M.; SHET, A. S.; SMYTH, S. S.; JOHNSON, G. J.

Favourites:
ADD

Free Content A guide to murine fibrinolytic factor structure, function, assays, and genetic alterations
pp. 680-689(10)
Authors: MATSUO, O.; LIJNEN, H. R.; UESHIMA, S.; KOJIMA, S.; SMYTH, S. S.

Favourites:
ADD
Favourites:
ADD

Free Content Incidence and mortality of venous thrombosis: a population-based study
pp. 692-699(8)
Authors: NÆSS, I. A.; CHRISTIANSEN, S. C.; ROMUNDSTAD, P.; CANNEGIETER, S. C.; ROSENDAAL, F. R.; HAMMERSTRØM, J.

Favourites:
ADD

Free Content Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy
pp. 700-707(8)
Authors: COCHERY-NOUVELLON, É.; MERCIER, É.; LISSALDE-LAVIGNE, G.; DAURÈS, J.-P.; QUÉRé, I.; DAUZAT, M.; MARÈS, P.; GRIS, J.-C.

Favourites:
ADD

Free Content Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders
pp. 708-714(7)
Authors: DE STEFANO, V.; FIORINI, A.; ROSSI, E.; ZA, T.; FARINA, G.; CHIUSOLO, P.; SICA, S.; LEONE, G.

Favourites:
ADD

Free Content Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD)
pp. 715-721(7)
Authors: TOSETTO, A.; RODEGHIERO, F.; CASTAMAN, G.; BERNARDI, M.; BERTONCELLO, K.; GOODEVE, A.; FEDERICI, A. B.; BATLLE, J.; MEYER, D.; MAZURIER, C.; GOUDEMAND, J.; EIKENBOOM, J.; SCHNEPPENHEIM, R.; BUDDE, U.; INGERSLEV, J.; VORLOVA, Z.; HABART, D.; HOLMBERG, L.; LETHAGEN, S.; PASI, J.; HILL, F.; PEAKE, I.

Favourites:
ADD

Free Content A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3
pp. 722-728(7)
Authors: SCHNEPPENHEIM, R.; CASTAMAN, G.; FEDERICI, A. B.; KREUZ, W.; MARSCHALEK, R.; OLDENBURG, J.; OYEN, F.; BUDDE, U.

Favourites:
ADD

Free Content The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials
pp. 729-737(9)
Authors: LAZO-LANGNER, A.; GOSS, G. D.; SPAANS, J. N.; RODGER, M. A.

Favourites:
ADD
Favourites:
ADD

Free Content A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement
pp. 746-753(8)
Authors: AGNELLI, G.; HAAS, S.; GINSBERG, J. S.; KRUEGER, K. A.; DMITRIENKO, A.; BRANDT, J. T.

Favourites:
ADD

Free Content Ethnic differences in cardiovascular risk factors in healthy Caucasian and South Asian individuals with the metabolic syndrome
pp. 754-760(7)
Authors: AJJAN, R.; CARTER, A. M.; SOMANI, R.; KAIN, K.; GRANT, P. J.

Favourites:
ADD

Free Content Indices of platelet activation and the stability of coronary artery disease
pp. 761-765(5)
Authors: LINDEN, M. D.; FURMAN, M. I.; FRELINGER, A.L.; FOX, M. L.; BARNARD, M. R.; LI, Y.; PRZYKLENK, K.; MICHELSON, A. D.

Favourites:
ADD

Free Content Elevated plasma fibrinogen γ′ concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors
pp. 766-773(8)
Authors: MANNILA, M. N.; LOVELY, R. S.; KAZMIERCZAK, S. C.; ERIKSSON, P.; SAMNEGÅRD, A.; FARRELL, D. H.; HAMSTEN, A.; SILVEIRA, A.

Favourites:
ADD

Free Content A cross-reactive material positive variant of coagulation factor XI (FXIP520L) with a catalytic defect
pp. 781-787(7)
Authors: GAILANI, D.; SCHMIDT, A.; SUN, M.-F.; BOLTON-MAGGS, P. H.; BAJAJ, S. P.

Favourites:
ADD

Free Content Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion
pp. 788-796(9)
Authors: KAUFMAN, J.; SPINELLI, S. L.; SCHULTZ, E.; BLUMBERG, N.; PHIPPS, R. P.

Favourites:
ADD

Free Content TAFIa, PAI-1 and α2-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots
pp. 812-817(6)
Authors: MUTCH, N. J.; THOMAS, L.; MOORE, N. R.; LISIAK, K. M.; BOOTH, N. A.

Favourites:
ADD

Free Content Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte–endothelial cell interactions
pp. 818-825(8)
Authors: IWAMA, D.; MIYAMOTO, K.; MIYAHARA, S.; TAMURA, H.; TSUJIKAWA, A.; YAMASHIRO, K.; KIRYU, J.; YOSHIMURA, N.

Favourites:
ADD

Free Content Characterization of endothelial-like cells derived from human mesenchymal stem cells
pp. 826-834(9)
Authors: LIU, J. W.; DUNOYER-GEINDRE, S.; SERRE-BEINIER, V.; MAI, G.; LAMBERT, J.-F.; FISH, R. J.; PERNOD, G.; BUEHLER, L.; BOUNAMEAUX, H.; KRUITHOF, E. K. O.

Favourites:
ADD

Free Content Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms
pp. 835-845(11)
Authors: GRANATA, R.; TROVATO, L.; LUPIA, E.; SALA, G.; SETTANNI, F.; CAMUSSI, G.; GHIDONI, R.; GHIGO, E.

Favourites:
ADD

Free Content Identification of key residues involved in mediating the in vivo anti-tumor/anti-endothelial activity of Alphastatin
pp. 846-854(9)
Authors: STATON, C. A.; STRIBBLING, S. M.; GARCÍA-ECHEVERRÍA, C.; BURY, J. P.; TAZZYMAN, S.; LEWIS, C. E.; BROWN, N. J.

Favourites:
ADD

Free Content Preanalytical conditions that affect coagulation testing, including hormonal status and therapy
pp. 855-858(4)
Authors: BLOMBÄCK, M.; KONKLE, B. A.; MANCO-JOHNSON, M. J.; BREMME, K.; HELLGREN, M.; KAAJA, R.

Favourites:
ADD

Free Content JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis
pp. 859-861(3)
Authors: REGINA, S.; HERAULT, O.; D'ALTEROCHE, L.; BINET, C.; GRUEL, Y.

Favourites:
ADD

Free Content Prognostic value of annexin A5 −1 C/T polymorphism in a long term follow-up after premature myocardial infarction
pp. 862-863(2)
Authors: ROLDÁN, V.; MARÍN, F.; GONZáLEZ-CONEJERO, R.; CORRAL, J.; VICENTE, V.

Favourites:
ADD

Free Content Plasma fibronectin levels and coronary artery disease
pp. 864-866(3)
Authors: VAVALLE, J. P.; WU, S. S.; HUGHEY, R.; MADAMANCHI, N. R.; STOUFFER, G. A.

Favourites:
ADD

Free Content von Willebrand factor collagen binding assay with a commercial kit using type III collagen in von Willebrand disease type 2
pp. 868-870(3)
Authors: VEYRADIER, A.; TROSSAERT, M.; LEFRANCOIS, A.; FRESSINAUD, E.; MEYER, D.

Favourites:
ADD

Free Content Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells
pp. 870-872(3)
Authors: GOON, P. K. Y.; WATSON, T.; SHANTSILA, E.; BOOS, C. J.; LIP, G. Y. H.

Favourites:
ADD

Free Content Influence of the Thr325Ile polymorphism on procarboxypeptidase U (thrombin-activable fibrinolysis inhibitor) activity-based assays
pp. 872-875(4)
Authors: WILLEMSE, J. L.; MATUS, V.; HEYLEN, E.; MEZZANO, D.; HENDRIKS, D. F.

Favourites:
ADD

Free Content Dietary supplement use among anticoagulation clinic patients
pp. 875-877(3)
Authors: WITTKOWSKY, A. K.; BUSSEY, H. I.; WALKER, M. B.; FREI, C. R.

Favourites:
ADD

Free Content Incidence of five prothrombotic gene polymorphisms in healthy Saudi Arabians
pp. 877-878(2)
Authors: MAMMO, L.; SHEEREEN, A.; SAOUR, T.; SHOUKRI, M.; SAOUR, J.

Favourites:
ADD

Free Content Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases
pp. 879-881(3)
Authors: ALEIL, B.; ROCHOUX, G.; MONASSIER, J.-P.; CAZENAVE, J.-P.; GACHET, C.

Favourites:
ADD

Free Content The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab
pp. 881-883(3)
Authors: VAN WERKUM, J. W.; VAN DER STELT, C. A. K.; SEESING, T. H.; TEN BERG, J. M.; HACKENG, C. M.

Favourites:
ADD

Free Content Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?
pp. 884-886(3)
Authors: VAN WERKUM, J. W.; KLEIBEUKER, M.; MIEREMET, N.; TEN BERG, J. M.; HACKENG, C. M.

Favourites:
ADD

Free Content In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban
pp. 886-888(3)
Authors: GEROTZIAFAS, G. T.; ELALAMY, I.; DEPASSE, F.; PERZBORN, E.; SAMAMA, M. M.

Favourites:
ADD

Free Content ANNOUNCEMENTS
pp. 890-891(2)

Favourites:
ADD

Free Content ERRATUM
pp. 892-892(1)

Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more